611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
CDC Updates Zika Guidance for Infant CareHealth Tip: Recognize Symptoms of Latex AllergyExercising With Asthma or AllergiesCan Aspirin Stop Liver Cancer in Hepatitis B Patients?Pollution Tied to 9 Million Deaths Worldwide in 2015Health Tip: Protect Yourself Against Breast CancerSkip Opioid Treatment for Migraine in the ERPPI Use Linked to Increased Risk of Ischemic Stroke, MINew Genes Linked to Restless Legs SyndromeAvoiding Alcohol Helps the Heart Beat Better2 Million Americans May Have Arsenic in Their Well WaterFirefighters Exposed to Carcinogens Through the SkinNewer Blood Thinners May Not Bring Higher Bleeding RiskScoliosis Screenings Can Help Catch Spine Problem EarlyArthritis Can Strike ChildrenHealth Tip: Relieve Ear Pressure While FlyingBlack Children Missing Out on Eczema TreatmentNew Framework Guides Tx Decisions for Atopic DermatitisHealth Tip: Recognizing SepsisAround the World, Too Little Relief for PainNearly 4 in 10 U.S. Adults Now ObeseFDA Panel Supports Gene Therapy for Kids With Rare Eye Disease30-Day Mortality Lower With Female SurgeonsDirect Primary Care May Fill Niche for Uninsured3 Factors That Could Raise Your Risk of Bloodstream InfectionStroke Risk Factors Are RisingTwo Ebola Vaccines Spur Lasting Immune ResponseHormone Therapy May Be OK for Women With MigrainesMigraine MattersMedial Temporal Lobe Surgery Linked to Prevalence of TinnitusHigher Levels of Fungus ID'd in Patients With Crohn'sWhere There's Type 1 Diabetes, Celiac Disease May FollowAntibiotic Use Not Linked to Islet, Celiac Disease AutoimmunitySome U.S. Olympians Got West Nile in Brazil, But Not ZikaPenicillin Misconceptions May Raise Post-Op Infection RiskHate UTIs? One Simple Step Can Cut the RiskIDSA: Retail Meat May Be a Transmission Source for UTIsLonger Anesthesia Duration Tied to More Surgical ComplicationsFirst Test to Detect Zika in Blood Donations ApprovedHealth Tip: Learn Symptoms of Childhood SinusitisLimiting 'Cold Time' Could Make More Organs Available for TransplantHealth Literacy Linked to Length of Stay After Abdominal SurgeryZika Vaccine Works in Early Human TrialHealth Tip: Understanding Loud Noise and Hearing LossAllergy Relief Do's and Don'tsPatient Factors Differ for Surgical, All-Cause ReadmissionComing Soon: A Faster Test for Antibiotics Against UTIs?Antibody Injections in Pregnancy Might Shield Fetus From ZikaHealth Tip: Giving BloodMore U.S. Measles Cases From No Vaccine vs. Imported Disease
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Diabetes Drug Shows Promise Against Parkinson's

HealthDay News
by -- Robert Preidt
Updated: Aug 4th 2017

new article illustration

FRIDAY, Aug. 4, 2017 (HealthDay News) -- The diabetes drug exenatide (Byetta) may do double duty as a treatment for Parkinson's disease, a new study suggests.

"This is a very promising finding, as the drug holds potential to affect the course of the disease itself, and not merely the symptoms," said senior study author Tom Foltynie, from University College London's Institute of Neurology.

"With existing treatments, we can relieve most of the symptoms [of Parkinson's] for some years, but the disease continues to worsen," he said in a university news release. "This is the strongest evidence we have so far that a drug could do more than provide symptom relief for Parkinson's disease."

Parkinson's is the second most common neurodegenerative disease worldwide, the researchers noted. The condition results in muscle stiffness, slowed movement, tremors, sleep disturbance and chronic fatigue.

In the study, 60 people with Parkinson's received either a weekly injection of exenatide or an inactive placebo for 48 weeks, along with their regular medications.

At the end of that period, those who took the diabetes drug scored four points higher on a 132-point scale of agility, speech and tremors than those who took the placebo. The difference was statistically significant, the study authors said.

The findings were published Aug. 3 in the The Lancet.

According to Brian Fiske, senior vice president of research programs at The Michael J. Fox Foundation for Parkinson's Research, "Using approved therapies for one condition to treat another, or drug repurposing, offers new avenues to speed Parkinson's therapeutic development." The foundation funded the study.

"The results from the exenatide studies justify continued testing, but clinicians and patients are urged not to add exenatide to their regimens until more is known about their safety and impact on Parkinson's," Fiske said.

Another Parkinson's expert agreed that more research is in order.

"While these are exciting findings, the observed benefit was small and only in one outcome-measure," said Dr. Martin Niethammer, a neurologist at Northwell Health's Neuroscience Institute, in Manhasset, N.Y.

"This might relate to the study being relatively small and of short duration, rather than lack of efficacy [effectiveness] of exenatide, and more study is certainly needed," he noted.

"This trial does provide an excellent rationale for larger and longer trials, and it remains to be seen if exenatide, and drugs like it, truly have a disease-modifying effect or merely improve the symptoms of Parkinson's disease," Niethammer said.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on Parkinson's disease.